RVTY — Revvity, Inc.

Is RVTY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Oversold As of November 17, 2026

Revvity, Inc. (RVTY) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Diagnostics & Research) last closed at $148.85. The rating moved from Neutral to Oversold on November 17, 2026.

See all oversold Healthcare stocks →

AI analysis

Revvity, Inc. (RVTY) sits in resilient life‑sciences and biopharma services end markets that benefit from chronic therapy adoption and outsourcing trends, offering steady recurring revenue potential. Near‑term catalysts include sustained prescription flows through specialty channels and potential contract wins tied to large‑cap pharma activity. However, elevated regulatory scrutiny around Medicare Advantage, cautious market sentiment, and limited near‑term visibility on filings and social signals create execution and reimbursement risks. Over the next month the stock is likely to trade in a narrow band absent clear earnings or guidance surprises, with upside tied to visible contract cadence and downside tied to regulatory or reimbursement shocks.

Key factors

  • Revvity, Inc. (RVTY) operates in life‑sciences, diagnostics and biopharma services channels that benefit from secular demand for specialty care, infusion and biopharma outsourcing.
  • Exposure to distributor and specialty pharmacy flows could sustain recurring revenue and consumable/service demand as adoption of chronic injectable therapies expands.
  • Large‑cap pharma consolidation and partnership activity supports outsourcing and services vendors, creating potential M&A and contract-growth catalysts.
  • Relatively steady demand profile and recurring components of revenue may provide defensive characteristics in risk‑off market windows.
  • Near‑term market tone is cautious with defensive flows dominating, which limits conviction for broad upside in the short run.
  • Limited available public filings and social sentiment data in the provided window increases uncertainty around recent operational execution and guidance changes.

Risks

  • Regulatory pressure from CMS package increasing Medicare/MA compliance and potential clawbacks, which can compress reimbursement or increase customer costs.
  • Customer concentration or contract renewal risk with large institutional buyers could materially impact revenue if renewals are delayed or unfavorable.
  • Reimbursement and pricing pressure across diagnostics and services markets, particularly if payors tighten coverage or margins.
  • Macro and rate sensitivity that could reduce hospital/OR capital spending or slow elective procedure volumes.
  • Execution risk around integration, new product rollouts, or conversion of pipeline contracts into revenue.
  • Limited near‑term visibility due to lack of fresh EDGAR filings and social/research signals in the provided data window.

See today's live rating, score and targets

Members see the live hourly rating for RVTY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.